Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Molecular Partners Ag ADR (NQ: MOLN )

6.120 +0.760 (+14.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,813
Open 6.210
Bid (Size) 5.300 (1)
Ask (Size) 9.210 (2)
Prev. Close 5.360
Today's Range 6.010 - 6.240
52wk Range 3.320 - 12.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
From Molecular Partners
Via GlobeNewswire

Performance

YTD
+46.76%
+46.76%
1 Month
+21.91%
+21.91%
3 Month
+1.83%
+1.83%
6 Month
+69.53%
+69.53%
1 Year
+43.33%
+43.33%

More News

Read More
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
From Molecular Partners
Via GlobeNewswire
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
From Molecular Partners
Via GlobeNewswire
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
From Molecular Partners
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
From Molecular Partners
Via GlobeNewswire
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
From Molecular Partners
Via GlobeNewswire
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
From Molecular Partners
Via GlobeNewswire
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Smith & Wesson Brands, Abacus Life And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
From Molecular Partners
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
From Molecular Partners
Via GlobeNewswire
Why Broadcom Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.